#ESC25: Alnylam to kick off CV events trial of zilebesiran despite mid-stage blood pressure miss

MADRID — Alnylam Pharmaceuticals said it will start a Phase 3 cardiovascular outcomes trial of its hypertension therapy zilebesiran this year, despite data showing the drug failed in a mid-stage study. Called KARDIA-3, the Phase 2 ...